Fierce Biotech reports in 2021 that Aetion, a real-world evidence platform, has secured $110 million in a series C funding round led by Warburg Pincus. The platform is known for compiling and analyzing real-world data from various sources to assess the safety and effectiveness of medical products. During the COVID-19 pandemic, Aetion worked with the FDA to gather data, renewing 100% of its contracts in 2020 and nearly doubling its revenues. The new funding will be used to enhance the platform's capabilities, expand the commercial team, and increase the company's presence in Europe and the Asia-Pacific region.
Read More
Read More